Clinical Trials Logo

Spondylitis, Ankylosing clinical trials

View clinical trials related to Spondylitis, Ankylosing.

Filter by:

NCT ID: NCT00558506 Recruiting - Clinical trials for Ankylosing Spondylitis

Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis

Aba-AS-01
Start date: January 2008
Phase: Phase 2
Study type: Interventional

This is an open-label trial investigating the efficacy and safety of abatacept in ankylosing spondylitis. It is planned to treat 30 patients with ankylosing spondylitis from baseline up to week 30. Abatacept will be administered intravenously according to the prescription used in rheumatoid arthritis.

NCT ID: NCT00544557 Completed - Clinical trials for Ankylosing Spondylitis

Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

Start date: October 2007
Phase: Phase 4
Study type: Observational

This study aims to provide a holistic assessment of patients receiving etanercept in a real-world setting.

NCT ID: NCT00517101 Not yet recruiting - Psoriatic Arthritis Clinical Trials

Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy

Start date: September 2007
Phase: N/A
Study type: Observational

A relationship between IBD and spondyloarthropathy is well recognized. ASCA ( anti saccharomyces cerevisiae antibodies)are considered to be a serological marker for Crohn's disease and have been studied in patients with spondyloarthropathy with conflicting results. More recently, new serological markers for IBD have been described. These markers are antibodies to certain defined glycans , and their use may permit an improved diagnosis of IBD. The aim of our study is to investigate wether these new serological markers are present in the sera of patients with spondyloarthropathy.

NCT ID: NCT00507403 Completed - Clinical trials for Ankylosing Spondylitis

Infliximab and Methotrexate in Ankylosing Spondylitis

SPAXIM
Start date: October 2007
Phase: Phase 4
Study type: Interventional

There is a great individual variability of pharmacokinetic of infliximab in patients treated for ankylosing spondylitis (AS). Moreover, some patients have a treatment with methotrexate (MTX), others have not. Thus, the aim of this study is to assess the effect of MTX on the pharmacokinetic properties of infliximab in 30 patients treated for AS, 15 with MTX, 15 without.

NCT ID: NCT00478660 Completed - Clinical trials for Ankylosing Spondylitis

An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)

RHAPSODY
Start date: February 2006
Phase: Phase 3
Study type: Interventional

Due to the rigor of the clinical development program of adalimumab for the indication of AS, the population of subjects with active AS that could enroll in previous phase 3 studies was limited. Therefore, it is necessary to further evaluate the use of adalimumab in a setting that mimics day-to-day clinical practice to obtain further safety and efficacy data by allowing subjects meeting the characteristics noted below to enter this study: - Subjects who failed another TNF inhibitor (etanercept, infliximab) - Subjects with advanced spinal ankylosis - Subjects with AS associated disorders (i.e., uveitis, IBD, and psoriasis)

NCT ID: NCT00458185 Completed - Clinical trials for Ankylosing Spondylitis

Study Evaluating Etanercept in Patients With Ankylosing Spondylitis

Start date: August 2006
Phase: Phase 4
Study type: Interventional

This study will assess the efficacy of etanercept for the treatment of Ankylosing Spondylitis (AS).

NCT ID: NCT00444340 Completed - Clinical trials for Ankylosing Spondylitis

An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis

Start date: April 2004
Phase: Phase 4
Study type: Interventional

This study is an extension trial of 0881A3-312-EU and is designed to provide information on the safety and efficacy of etanercept in patients with ankylosing spondylitis for up to 3 additional years.

NCT ID: NCT00439283 Completed - Clinical trials for Ankylosing Spondylitis

Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis

Start date: April 2003
Phase: Phase 3
Study type: Interventional

Continuous treatment with the anti-tumor necrosis factor alpha monoclonal antibody infliximab is efficacious in ankylosing spondylitis (AS), whereas treatment discontinuation results in disease relapse, with variable delay. Objective of this study was to compare efficacy between a continuous treatment with infliximab, and a treatment adapted to symptoms recurrence. Addition of methotrexate (MTX)to infliximab was also tested.

NCT ID: NCT00434044 Completed - Clinical trials for Ankylosing Spondylitis

Study Evaluating Etanercept in the Treatment of Subjects With Ankylosing Spondylitis

Start date: February 2007
Phase: Phase 3
Study type: Interventional

This study will represent the sponsor's first controlled study of etanercept in Chinese subjects with Ankylosing Spondytitis (AS). This trial is designed to assess the safety and efficacy of etanercept compared to placebo in the treatment of patients with AS.

NCT ID: NCT00432653 Unknown status - Clinical trials for Ankylosing Spondylitis

Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis

Start date: March 2007
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy and safety of rituximab when added to NSAIDs and/ or methotrexate both for TNFalpha inhibitor naïve or TNFalpha inhibitor failure patients with moderate to severe ankylosing spondylitis